Eli Lilly and Company News - March 19, 2026

Eli Lilly Retatrutide Hits Phase 3 Goals, Cutting Weight by Nearly 17%

Eli Lilly and Company announced positive topline results from the TRANSCEND-T2D-1 Phase 3 trial. The investigational drug retatrutide met all primary and...

Eli Lilly Invests $1.8 Billion in Indianapolis, Boosting Complex Peptide Production

Eli Lilly and Co. will invest up to $1.8 billion to modernize its research and manufacturing facilities in Indianapolis. The multi-year project expands...